Bioton SA &
Polpharma SA | Update Date: 10/15/08 |
| Date Announced: 08/15/08 |
Value (million $USD): 198.7 million U.S. Dollar
450.0 million Polish Zloty |
|
| Status: Pending | |
| TRANSACTION DETAILS |
|---|
| Date Announced | 08/15/08 | | |
| Date Originally Announced | 08/15/08 | | |
| Format | Acq. Part. Int. | Acquisition techniques | Privately Negotiated Purc |
| Attitude | Neutral | Agency | n/a |
| Value | 198.7 million U.S. Dollar
450.0 million Polish Zloty | Advisor Fees | n/a |
| SYNOPSIS |
|---|
| POLAND - Polpharma SA, through an undisclosed subsidiary, planned to acquire a 33.3% stake, or 1.019 bil ordinary shares, in Bioton SA, a Warsaw-based manufacturer of pharmaceutical products, from Prokom Investments SA, for 450 mil Polish zlotych (198.675 mil US), in a privately negotiated transaction. |
| TARGET |
|---|
| Name | Bioton SA (Warsaw : BIO) |
| Industries | Medicinal chemicals and botanical products; Biological products, except diagnostic substances |
| City | Warsaw |
| State | n/a |
| Nation | Poland |
| Incorporated in | n/a |
| Public Status | Public |
| Business Description | Bioton SA is a pharmaceutical manufacturing firm, headquartered in Warsaw, Poland and with locations in Switzerland, Italy, Ukraine, Russia, Cyprus, Kazakhstan, India, South Korea, Singapore and Australia. The company's products include Recombinant human insulin, Glimepiride, Cephalosporine antibiotics, Aminoglycoside antibiotics, Macrolide antibiotics, Anthracyclines, and Antimetabolites. The company was founded in 1989. |
| Advisors | NULL |
| Target Sales | 152.6 million U.S. Dollar
324.0 million Polish Zloty |
|
| ACQUIROR |
|---|
| Name | Polpharma SA |
| Industries | Medicinal chemicals and botanical products; Biological products, except diagnostic substances |
| City | Starogard Gdanski |
| State | n/a |
| Nation | Poland |
| Incorporated in | n/a |
| Public Status | Subsidiary |
| Business Description | Polpharma SA, located in Starogard Gdanski, manufactures pharmaceutical drugs and active pharmaceutical ingredients focused in cardiological, gastrological and neurological and therapeutic drugs used to treat patients with ischemic heart disease and type 2 diabetes mellitus, as well as medicines for gastroenterology, neurology, pulmonology, anti-infective drugs and dermatology. Polpharma also manufactures over the counter drugs such as analgesics, cold and influenza medicines, gastric disorders and ophthalmic drugs, and pediatric drugs and vitamin supplements, manufactured by Medana Pharma Terpol Group SA. The company also manufactures active pharmaceutical ingredients such as Acetazolamide, Acyclovir, Alendronate sodium, Baclofen, Bupropion hydrochloride, Carbamazepine, Carvedilol, Cyclobenzaprine hydrochloride, Enalapril maleate, Entacapone, Ethenzamide, Etodolac, Hydrochlorithiazide, Lamotrigine, Metoclopramide hydrochloride, Metoprolol tartrate, Metoprolol succinate, Metronidazole, Montelukast sodium, Opipramol dihydrochloride, Pentoxifylline, Phenyl Salicylate, Piracetam, Repaglinide, Risedronate sodium, Salicylamide, Sildenafil salicylate, Sulfadimethoxine, Sulfadimethoxine sodium, Tinidazole and Topiramate, as well as parenteral drugs, injectable preparations in polyethylene packagings and glass ampoules, eye and nasal drops, infusion fluids, used to treat illnesses that affects the alimentary tract, cardiovascular, central nervous, musculo-skeletal and respiratory systems. |
| Advisors | NULL |
| Acquiror Sales | n/a |
|
 |
|
